| |
NewswireTODAY - /newswire/ -
Chicago, IL, United States, 2015/02/10 - Session to Address Current FDA Regulatory Landscape and Impact of 3D Printing Strategies for Protecting Intellectual Property - Q1Productions.com.
|
| |
By popular request, the Medical Device and Diagnostic Intellectual Property and Patent Strategy Conference will offer an in-depth look at the impact of 3D printing on Medical Device and Diagnostic industries and address strategies for protecting intellectual property related to 3D printing. The interactive session will be led by Sonali Gunawardhana, Counsel at Wiley Rein LLP.
The new session, titled “The Innovative World of 3D Printed Medical Devices, IP and FDA Considerations -- What You Need to Know” will focus on the regulatory challenges of the FDA and technical issues that 3D printing poses to the FDA, despite numerous submissions for both traditional and patient-matched devices. Conference delegates will discuss identifying factors related to 3D printing that IP counsel should consider when developing a protection strategy, reviewing the challenges that lie ahead for those seeking FDA clearance and approval of devices, and understanding key messages and questions still posed from the recent FDA stakeholder meeting regarding 3D printing.
In addition to the newest session, the conference will offer a wide variety of sessions, panels, and workshops on topics such as prioritizing budgets in-house, assessing innovative technologies, global patent filings for cost reduction, and much more. Speakers include Kevin Ferguson of Covidien, Jamie Kemler of Stryker, and Norman Hainer of Smith & Nephew, and delegates will have the chance to partake in open-floor discussion, networking opportunities, and more.
For more information on the Medical Device and Diagnostic Intellectual Property and Patent Strategy Conference, please email marketing[.]q1productions.com.
About the Organizer
Q1 Productions (q1productions.com) designs and develops webinars, training courses, conference programs and forums aimed at specifically targeted audiences throughout highly regulated industries in order to provide strategic learning and timely program content. Through a highly structured production process focused on research calls with end-users and key stakeholders in the industry, our team is able to understand the immediate business concerns of today’s leading executives. Whether focusing on new or pending legislative and health policy issues or enhanced technologies or processes that will drive efficiency, our programs provide solutions to the urgent educational and information needs of our attendees.
|
eabdnour[.]q1productions.com 
